The FDA has granted a priority review to ADC Therapeutics’ antibody-drug conjugate (ADC) Lonca in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ADC is set to learn whether it has won approval for a drug it sees as the future standard of care in third-line DLBCL in May.

GE Healthcare has moved to acquire a Swedish startup and its next-generation photon-counting technology, which the medtech manufacturer says could help expand the clinical reach of its CT scanners.

A small number of cancer patients respond particularly well to drugs. These so-called “exceptional responders” not only see their tumors shrink with treatment, they also enjoy responses that are unusually long. Understanding of the molecular features of this rare group of patients could guide the development of new strategies for fighting cancer.

Having spent over 20 years working with customers in the life sciences industry, I’m well aware of the challenges medical device companies face when it comes to training surgeons. Almost all training is done in person, whether in the OR, clinic, or simulation center, which is not always the most efficient. And over time, these face-to-face meetings get extremely expensive.

You may not be thinking about the future scale-up to commercial production when you’re in the early stages of crafting a new biologic therapy. But it is prudent to keep your long-term production needs in mind.

CSL Behring and uniQure’s hemophilia B gene therapy etranacogene dezaparvovec hit its primary endpoint in an ASH late-breaker posted today.

Following an upbeat release of top-line data earlier this year that showed its finerenone treatment helped stave off kidney and heart disease, Bayer is now providing more details on the drug’s ability to improve the health of chronic patients regardless of their past history of cardiovascular conditions.

Deep Genomics is wasting no time. Two weeks after hiring a new chief business officer to ramp up its partnering game, it’s unveiling its first biopharma tie-up: BioMarin. The duo will use the Toronto biotech’s artificial-intelligence-based drug discovery platform to discover new drugs for rare diseases.

Boston Scientific has retired its entire Lotus Edge heart valve program, effective immediately, leaving a gap in the company’s U.S. transcatheter aortic valve replacement offerings until a new model is approved by the FDA.

Avrobio has shared data on the first Gaucher disease patient to receive its gene therapy AVR-RD-02. The patient, who was stable on enzyme replacement therapy at baseline, experienced a 22% drop in a toxic metabolite after receiving AVR-RD-02 and stopping taking the standard of care.